These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31511287)

  • 1. Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol.
    Balakumaran J; Birk T; Golemiec B; Helmeczi W; Inkaran J; Kao YY; Leigh J; Saliba S; Sharma R; Spatafora L; Wright K; Yao W; Hillis C; Banfield L; Thabane L; Athale U; Samaan MC
    BMJ Open; 2019 Sep; 9(9):e030092. PubMed ID: 31511287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overweight and obesity management strategies in survivors of paediatric acute lymphoblastic leukaemia: a systematic review protocol.
    Ladhani S; Empringham B; Wang KW; Portwine C; Banfield L; de Souza RJ; Thabane L; Samaan MC
    BMJ Open; 2018 Jun; 8(6):e022530. PubMed ID: 29934396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.
    Breccia M; Molica M; Alimena G
    Leuk Res; 2014 Dec; 38(12):1392-8. PubMed ID: 25449685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia.
    Millot F; Maledon N; Guilhot J; Güneş AM; Kalwak K; Suttorp M
    Eur J Cancer; 2019 Jul; 115():17-23. PubMed ID: 31082688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective components of exercise and physical activity-related behaviour-change interventions for chronic non-communicable diseases in Africa: protocol for a systematic mixed studies review with meta-analysis.
    Igwesi-Chidobe CN; Godfrey EL; Kengne AP
    BMJ Open; 2015 Aug; 5(8):e008036. PubMed ID: 26270945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-adherence to CML therapy and its clinical implications in India.
    Menon H
    Natl Med J India; 2017; 30(3):142-147. PubMed ID: 28936999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication experience and patient's related needs in chronic myeloid leukemia treated with tyrosine kinase inhibitors: Systematic review.
    Cachafeiro Pin AI; Villaverde Piñeiro L; Martín Clavo S; Silva Castro MM
    Farm Hosp; 2023; 47(2):85-92. PubMed ID: 36599752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A New Goal for Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: Treatment-free Remission -Review].
    Yang L; Wang BH; Jin XS; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1883-1887. PubMed ID: 28024513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peer influence in adolescent drinking behaviour: a protocol for systematic review and meta-analysis of stochastic actor-based modeling studies.
    Ivaniushina V; Titkova V; Alexandrov D
    BMJ Open; 2019 Jul; 9(7):e028709. PubMed ID: 31326933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
    Campiotti L; Suter MB; Guasti L; Piazza R; Gambacorti-Passerini C; Grandi AM; Squizzato A
    Eur J Cancer; 2017 May; 77():48-56. PubMed ID: 28365527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.